Cover Image

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

Show other versions (1)

The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with HF at baseline. These might indicate a potent direct card...

Full description

Saved in:
Bibliographic Details
Main Authors: Sayour, Alex Ali (Author) , Korkmaz-İçöz, Sevil (Author) , Loganathan, Sivakkanan (Author) , Ruppert, Mihály (Author) , Brune, Maik (Author) , Karck, Matthias (Author) , Szabó, Gábor (Author)
Format: Article (Journal)
Language:English
Published: 16 April 2019
In: Journal of translational medicine
Year: 2019, Volume: 17, Pages: 1-14
ISSN:1479-5876
DOI:10.1186/s12967-019-1881-8
Online Access:Verlag, Volltext: https://doi.org/10.1186/s12967-019-1881-8
Get full text
Author Notes:Alex Ali Sayour, Sevil Korkmaz-Icöz, Sivakkanan Loganathan, Mihály Ruppert, Viktor Nabil Sayour, Attila Oláh, Kálmán Benke, Maik Brune, Rita Benkő, Eszter Mária Horváth, Matthias Karck, Béla Merkely, Tamás Radovits and Gábor Szabó
Description
Summary:The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with HF at baseline. These might indicate a potent direct cardioprotective effect, which is currently incompletely understood. We sought to characterize the cardiovascular effects of acute canagliflozin treatment in healthy and infarcted rat hearts.
Item Description:Gesehen am 14.05.2019
Physical Description:Online Resource
ISSN:1479-5876
DOI:10.1186/s12967-019-1881-8

Similar Items